Komori
Zeria Pharmaceutical (4559) · FactAchieved

Recognition of a Provision for Contract Cancellation Losses

First written in FY2023-Q2. 3 of 6 entries say "Advanced", first in FY2023-Q3. Latest entry: FY2024.

6entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023-Q2AdvancedFY2023-Q3 – FY2024-Q1OtherFY2024-Q22022: 120222023: 420232024: 12024
Same theme, other companies
Recognition and Reversal of Provisions for Cancellation LossesA theme 4 companies write about · 3 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2024AchievedAnnual report

    「The main changes in non-current liabilities were a ¥6,597 million decrease in long-term borrowings, a ¥1,256 million increase in deferred tax liabilities, and an ¥897 million decrease in the provision for contract termination losses.」

    The provision for contract termination losses fell from ¥897.300 million at the end of the previous fiscal year to zero, and a reversal of ¥977.204 million was recognized as extraordinary income.
  2. FY2024-Q2Full reversal of the provision for contract termination losses and elimination of the balanceAnnual report

    「The main changes in non-current liabilities were a ¥2,523 million decrease in long-term borrowings and an ¥897 million decrease in the provision for contract termination losses.」

    The provision for contract termination losses fell from ¥897 million at the end of the previous consolidated fiscal year to zero, and the Company recognised a ¥923.331 million reversal of the provision as an extraordinary gain.
  3. FY2024-Q1AdvancedAnnual report

    「Provision for contract termination losses 897,300 912,407」

    The balance of the provision for contract termination losses increased from ¥897,300 thousand at the end of the previous consolidated fiscal year to ¥912,407 thousand.
  4. FY2023AdvancedAnnual report

    「¥322,472 thousand addition to the provision for contract termination losses」

    The Company recognised the ¥322,472 thousand addition to the provision for contract termination losses as an extraordinary loss, bringing the period-end balance to ¥897,300 thousand.
  5. FY2023-Q3AdvancedAnnual report

    「The main changes in non-current liabilities were a ¥2,291 million decrease in long-term borrowings and a ¥349 million increase in the provision for contract termination losses.」

    The provision for contract termination losses increased by ¥349 million from the end of the previous consolidated fiscal year to ¥839,851 thousand. In addition, ¥235,935 thousand was recognised as an extraordinary loss for the addition to the provision for contract termination losses.
  6. FY2023-Q2First statedAnnual report

    「¥319 million increase in the provision for contract termination losses」

    The provision for contract termination losses increased by ¥319 million at the end of the current second quarter, and ¥228.3 million was recognised as an extraordinary loss for the cumulative second quarter period as an addition to the provision for contract termination losses.
Moved together

"Strengthening the Foundation as a Global Company" moved the same way as this thread, in the same document, in 4 of its 6 moves.

444333★123456
  1. ★This thread
  2. 1Strengthening the Foundation as a Global Company4×
  3. 2Expansion of overseas sales4×
  4. 3Increase in the ratio of overseas sales4×
  5. 4Further Strengthening of the Financial Position3×
  6. 5Recovery in Revenue, Operating Profit and Net Income3×
  7. 6Expansion of the European and Other Businesses through the Transfer of the Marketing Rights for Dificlir Tablets3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.